ReviewCancers2026
Targeting the Epigenetic-Immune Axes in Hematologic Malignancies.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite significant advances in treatment for several hematologic malignancies, treatment resistance and relapse remain major challenges. Immune escape is recognized as a key mechanism that can lead to tumor evasion and treatment resistance in blood cancers. Among the various drivers of immune evasion, epigenetic dysregulation is a recurrent and central feature in these malignancies. Although epigenetic targeting therapies have shown benefit in blood cancers, relapse still occurs, indicating the need for improved therapies. This review focuses on epigenetic mechanisms causing immune evasion in blood cancers and discusses emerging therapies that focus on combining epigenetic modulators with immunotherapies to improve anti-tumor immunity. We focus on how epigenetic mechanisms, including DNA methylation, histone modification and chromatin remodeling, influence tumor cells or immune cell subsets including T cells, NK cells and macrophages to promote tumor growth. We then discuss immunomodulatory effects of epigenetic therapies including DNA methyltransferase inhibitors and histone deacetylase inhibitors and how they can restore immune cell function and limit tumor growth and progression. Finally, we highlight the potential of combining epigenetics with different immunotherapies including adoptive cell therapy and immune checkpoint blockade, while discussing their current limitations and suggesting ways to overcome this therapy resistance. A deeper understanding of the immune-epigenetic axis in blood cancers may facilitate the development of effective therapies that will benefit patients with hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.